Skip to content

Trial Summary

The primary purpose of this trial is to evaluate the safety and tolerability of Metformin (MET) in combination with sodium valproate (VPA) for the treatment of prostate cancer.

Acronym:

Viper

ACTRN/NCT /ethics:

ACTRN12616001021460

Scientific title:

Sodium Valporate/ Metformin combination therapy for prostate cancer (VIPER 1 trial)

Sponsor / Cooperative group:

Flinders University

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexMale
Tumour Stream -
Cancer StageEarly\In Situ; Locally Recurrent or Locally Advanced
Anticipated Start Date2016-12-01
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting